Sciot, Raf <br/><br/>
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Sep 2008 
 - 1855-60 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2008.06.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, CD34--metabolism<br/>Antineoplastic Agents--administration & dosage<br/>Benzamides<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Exons<br/>Female<br/>Gastrointestinal Stromal Tumors--drug therapy<br/>Humans<br/>Imatinib Mesylate<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Male<br/>Mutation--genetics<br/>Piperazines--administration & dosage<br/>Proto-Oncogene Proteins c-kit--genetics<br/>Pyrimidines--administration & dosage<br/>Receptor, Platelet-Derived Growth Factor alpha--genetics